Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.
Summary
This preclinical study establishes BMAL1 as a macrophage-centric therapeutic node in SA-ARDS and demonstrates an inhalable, AM-targeted nanovesicle that activates BMAL1 to repress PFKFB3-driven glycolysis. The treatment reduced lung inflammation, edema, and improved survival in murine SA-ARDS, highlighting a translatable metabolic-immunologic strategy.
Key Findings
- BMAL1 represses PFKFB3, limiting glycolysis and M1 polarization in alveolar macrophages.
- An inhalable biomimetic nanoplatform (RM@TNT) targets AMs and activates BMAL1 in a ROS-rich lung microenvironment.
- RM@TNT reduced lung inflammation, injury, and edema and significantly improved survival in SA-ARDS mice.
Clinical Implications
While preclinical, the work supports inhaled, macrophage-targeted metabolic reprogramming in SA-ARDS and prioritizes BMAL1 activation as a therapeutic avenue warranting translational development and safety testing.
Why It Matters
It uncovers a circadian-metabolic checkpoint (BMAL1/PFKFB3) in ARDS pathobiology and delivers a targeted, inhalable nanotherapy with survival benefit in vivo.
Limitations
- Preclinical murine model; species differences may limit translatability.
- Safety, biodistribution, and manufacturability of the nanoplatform were not fully characterized.
Future Directions
Conduct GLP toxicology, pharmacokinetics, and dose-ranging studies, refine inhalation formulations, and explore biomarkers (BMAL1/PFKFB3 activity) to enable early-phase clinical trials in SA-ARDS.
Study Information
- Study Type
- Case-control
- Research Domain
- Treatment
- Evidence Level
- V - Preclinical in vivo and in vitro experimental evidence without human subjects.
- Study Design
- OTHER